BTCA — Bactolac Pharmaceutical Income Statement

0.000.00%

Last trade - 00:00

Consumer DefensivesMid Cap

Annual income statement for Bactolac Pharmaceutical, fiscal year end - September 30th, USD millions except per share, conversion factor applied.

	R2001 September 30th	C2002 September 30th	R2003 September 30th	2004 September 30th	2005 September 30th
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10KSB	10KSB	10KSB
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	17.6	21.6	12.8	17.6	22.9
Cost of Revenue
Gross Profit	5.02	6.34	4.69	6.03	6.33
Selling / General / Administrative Expenses
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	18.2	22.4	10.7	14.5	19.9
Operating Profit	-0.608	-0.817	2.14	3.18	3.02
Total Net Non Operating Interest Income / Expense
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-1.27	-2.16	1.94	2.9	2.8
Provision for Income Taxes
Net Income After Taxes	-0.981	-2.16	1.94	4.24	1.88
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	0.165	-3.35	-3.84	3.05	1.88
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	0.165	-3.35	-3.84	3.05	1.88
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-5,083	-8,815	3,972	7,765	3,346
Dividends per Share